T1D

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Retrieved on: 
Thursday, April 4, 2024
Partnership, T1D, Medtech, Conference, Immunotherapy, Pharmaceutical industry

Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the company’s Chairman and CEO, will present an overview of the company at the upcoming 23rd Annual Needham Virtual Conference on Thursday, April 11, 2024 at 1:30 p.m.

Key Points: 
  • Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the company’s Chairman and CEO, will present an overview of the company at the upcoming 23rd Annual Needham Virtual Conference on Thursday, April 11, 2024 at 1:30 p.m.
  • ET.
  • The company will also participate in virtual 1:1 meetings, and a replay of Mr. Reich’s presentation will be archived on the company website for up to one year.
  • Mr. Reich’s presentation is entitled, “Human Anti Thymocyte Biologic Developed to Delay Onset or Progression of Type 1 Diabetes.” This fully virtual conference will feature fireside chats and presentations from leading public and private companies in the biopharma, medtech, diagnostics and digital health sectors as well as thematic panel discussions.

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

Retrieved on: 
Monday, March 25, 2024
Disease, Development, Immunotherapy, Partnership, T1D, Patient, NMRC, Research, Mortality, Death, Breakthrough therapy, Infection, CDC, Vaccination, Safety, SAB, Therapy, Vaccine, Immunoglobulin G, Food

The NMRC Clinical Trials Center, located in Bethesda, Maryland, will be conducting this PK study under the leadership of Cmdr.

Key Points: 
  • The NMRC Clinical Trials Center, located in Bethesda, Maryland, will be conducting this PK study under the leadership of Cmdr.
  • SAB has utilized its proprietary DiversitAb™ platform to manufacture SAB-176, fully human polyclonal antibodies targeting influenza from Transchromosomic (Tc) Bovine™.
  • SAB-176 is a novel multi-target biologic that has shown sustained neutralization activity across multiple virus strains of Influenza A and B.
  • Influenza is responsible for approximately 226,000 excess hospitalizations and 30,000 to 50,000 deaths each year in the United States alone.

JDRF T1D Fund, a Leading Disease-Focused Venture Philanthropy Fund, Appoints Sylvia Tobé as Managing Director

Retrieved on: 
Wednesday, April 3, 2024
Genetics, Diabetes, Philanthropy, Other Health, Biotechnology, Fund Raising, Pharmaceutical, Health, Foundation, Other Philanthropy, Neurology, Growth, Synthetic biology, T1D, Merck, University, Doctor of Philosophy, Investment, Harvard University, Autoimmune disease, Pharmaceutical industry

The JDRF T1D Fund, a venture philanthropy investment fund focused on curing type 1 diabetes (T1D), announced today that Sylvia Tobé, PhD had joined as a Managing Director based in Boston.

Key Points: 
  • The JDRF T1D Fund, a venture philanthropy investment fund focused on curing type 1 diabetes (T1D), announced today that Sylvia Tobé, PhD had joined as a Managing Director based in Boston.
  • Dr. Tobé will work alongside the T1D Fund’s other Managing Directors and members of the investment team to advance and broaden the T1D Fund's investment activities and capabilities.
  • Dr. Tobé has a decade of life sciences industry experience and joins from Omega Funds, where she served as a Principal on the investment team.
  • Dr. Tobé also provided scientific leadership for multiple discovery programs within the company's internal pipeline and in collaboration with Merck.

Creative Medical Technology Holdings Provides Corporate Update

Retrieved on: 
Wednesday, March 27, 2024
Health, FDA, General Health, Clinical Trials, Research, Science, Biotechnology, Consultant, Toxicity, Radiation, Medicine, Urology, Immunotherapy, T1D, Patient, History, IND, Regenerative medicine, Gynaecology, Investment, IP, Investigational New Drug, Clinical trial, Safety, Pain, Share repurchase, Endocrinology, Elective surgery, Food, IRB, Pharmaceutical industry

Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update in connection with the filing of its Form 10-K on March 22, 2024.

Key Points: 
  • Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update in connection with the filing of its Form 10-K on March 22, 2024.
  • “In the past year our achievements have been some of the most consequential in the history of Creative Medical Technology,” said Timothy Warbington, the Company’s Chief Executive Officer.
  • We believe that our cell-based therapies have the potential to address critical unmet medical needs and are poised to pursue this objective.”
    He continued, “2023 was a year of significant achievement for Creative Medical, and our progress along multiple fronts has continued into 2024.
  • In Q1 2024, the Company announced the receipt of Orphan Drug Designation from the FDA for CELZ-101, or ImmCelz™.

JDRF Shines Light on Type 1 Diabetes During Autoimmune Awareness Month

Retrieved on: 
Tuesday, March 26, 2024
Community, Diagnosis, Research, Health, Vitiligo, Disease, Partnership, Insulin, Risk, T1D, Autoantibody, Pancreas, JDRF, Immune system, FDA, Clinical trial, Autoimmune disease, Pharmaceutical industry

NEW YORK, March 26, 2024 /PRNewswire/ -- In recognition of Autoimmune Awareness Month, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, recognizes all those who live with T1D, an autoimmune condition that causes the pancreas to make very little insulin or none at all. T1D is one of nearly 100 autoimmune diseases that occur when the body's immune system mistakenly attacks another part of the body. While there are currently no cures for autoimmune diseases, screening options may be available, which can reduce the risk of life-threatening complications at diagnosis and provide people time to develop a plan in partnership with their healthcare team. JDRF continues advancing breakthroughs to find cures for T1D, including research that has the potential to impact other autoimmune diseases.

Key Points: 
  • Screening for type 1 diabetes can reduce the risk of life-threatening complications at diagnosis.
  • NEW YORK, March 26, 2024 /PRNewswire/ -- In recognition of Autoimmune Awareness Month, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, recognizes all those who live with T1D, an autoimmune condition that causes the pancreas to make very little insulin or none at all.
  • JDRF continues advancing breakthroughs to find cures for T1D, including research that has the potential to impact other autoimmune diseases.
  • JDRF encourages those with T1D and other autoimmune diseases to share their stories and continue to build awareness of their conditions and opportunities for screening.

JDRF Proudly Announces the Appointment of New International Board of Directors Vice Chair

Retrieved on: 
Wednesday, March 13, 2024
Royal Bank of Canada, Partnership, Royal Bank, T1D, Research, Parent, McMaster University, JDRF, International Board, Management

NEW YORK and TORONTO, March 13, 2024 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, today announced the appointment of Matt Varey as the new vice chair of the non-profit's International Board of Directors. Matt, of Oakville, Ontario, is the first Canadian and first person from outside of the United States to hold the vice chair position. He is a senior executive at Royal Bank of Canada, the country's largest financial institution, where he is responsible for more than 4,500 Canada-based employees who manage personal investments, mortgage financing, and group benefits totaling more than $100 billion annually.  

Key Points: 
  • "We are delighted that Matt is taking on the role of vice chair of JDRF's International Board of Directors.
  • In addition to his work on JDRF's International Board of Directors, Matt serves on the board of JDRF Canada.
  • "I have been a JDRF volunteer for more than 20 years and am honored to step into the role of vice chair of JDRF's International Board of Directors", said Matt Varey.
  • Varey will be joined in his term of board leadership by Lisa Fishbone Wallack , the newly appointed chair of JDRF's International Board of Directors.

JDRF Celebrates Women's History Month with the Announcement of New International Board of Directors Chair

Retrieved on: 
Wednesday, March 13, 2024
Northern Tier (United States), University, T1D, Research, History, News, International Board, Benjamin, Royal Bank, Women's History Month, JDRF, Royal Bank of Canada, Family, Management

NEW YORK, March 13, 2024 /PRNewswire/ -- In celebration of Women's History Month, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly announces the appointment of Lisa Fishbone Wallack as the new chair of the nonprofit's International Board of Directors. Lisa, of Weston, Massachusetts, is an attorney by training and has volunteered with JDRF since childhood. Her brother was diagnosed with T1D as a toddler in 1969 and her son was diagnosed with the condition in 2001.

Key Points: 
  • "I am excited and proud to welcome Lisa into her new role as chair of JDRF's International Board of Directors," said Aaron J. Kowalski, Ph.D., CEO of JDRF.
  • Lisa has been a member of JDRF's International Board of Directors since 2015.
  • "It's an incredible honor to step into the role of chair of JDRF's International Board of Directors," said Lisa.
  • Lisa will be joined in her term of board leadership by Matt Varey, the newly appointed vice chair of JDRF's International Board of Directors.

INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

Retrieved on: 
Monday, March 11, 2024
Diabetes, Senior, Randomized controlled trial, Inhalable insulin, RAA, Teaching, Hyperglycemia, MannKind Corporation, AUC, A1C, Standard of care, Conference, ATTD, Safety, University, MDI, Patient, Insulin, Automation, Clinical trial, T1D, Pharmaceutical industry

INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.

Key Points: 
  • INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.
  • “In this large, randomized trial utilizing more appropriate dose conversion, we are excited to see meal challenge results support the safety and efficacy of inhaled insulin from the start.”
    INHALE-3 is a 17-week randomized controlled trial with a 13-week extension.
  • Subjects utilizing inhaled insulin received a higher initial conversion dose than in the current label.
  • For the meal challenge, the inhaled insulin group took an inhaled insulin dose immediately prior to a standardized meal (a 240 calorie nutritional shake) whereas those using usual care used RAA 5-15 minutes prior to the meal.

MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8

Retrieved on: 
Tuesday, March 5, 2024
Senior, Randomized controlled trial, RAA, Teaching, EST, Diabetes, MannKind Corporation, ABC, A1C, Standard of care, Conference, ATTD, University, MDI, Patient, Insulin, Automation, Clinical trial, T1D, Pharmaceutical industry

INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.

Key Points: 
  • INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.
  • “With ABC and this trial, we used a higher initial conversion dose for inhaled insulin than in our current label.
  • In the ABC study, this conversion dose produced significantly lowered post-prandial glucose levels that peaked 30 minutes sooner than standard of care.
  • More information on the study is available at: ClinicalTrials.gov(NCT05904743) .

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Retrieved on: 
Monday, March 4, 2024
Incidence, CGM, Doctor of Philosophy, Level 2, MD, FDA, Quality of life, IROS, Safety, Diabetes, Therapy, Type 2 diabetes, Patient, Insulin, T1D, Pharmaceutical industry

This randomized, double-blind, placebo-controlled trial is expected to enroll approximately 150 patients at up to 20 sites in the United States, with the first patient expected to be enrolled in the second quarter of 2024.

Key Points: 
  • This randomized, double-blind, placebo-controlled trial is expected to enroll approximately 150 patients at up to 20 sites in the United States, with the first patient expected to be enrolled in the second quarter of 2024.
  • The Phase 3 study will assess two doses of orally administered cadisegliatin versus placebo in patients currently being treated with multiple daily insulin injections and continuous subcutaneous insulin infusion, who use a continuous glucose monitor (CGM).
  • The primary efficacy endpoint of the study will compare the incidence of Level 2 or Level 3 hypoglycemic events between cadisegliatin-treated subjects and those in the placebo group.
  • Cadisegliatin is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use.